BeiGene
BeiGene
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Mar 01, 2021 11:55 AM
· Healthcare
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
In depth
Briefing Feb 05, 2021 02:07 PM
· Healthcare
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Staples, Real Estate, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Consumer Staples, Real Estate, Consumer DiscretionaryLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 20, 2020 02:22 PM
· Healthcare
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Briefing Dec 16, 2020 02:27 PM
· Healthcare
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Briefing Nov 19, 2020 09:33 AM
· Healthcare
Baiji Shenzhou: midterm analysis of the global phase III clinical trial for the treatment of non-small cell lung cancer reached the main end point
Briefing Jul 14, 2020 11:02 AM
· Healthcare
Hillhouse Will Inject USD 1 billion in BeiGene's Share Sale
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.